Berliner Boersenzeitung - Inside information: Bioretec's Board of Directors to initiate a new CEO recruitment process

EUR -
AED 3.956462
AFN 74.649948
ALL 101.849929
AMD 434.999699
ANG 1.943299
AOA 896.897542
ARS 391.891128
AUD 1.636563
AWG 1.939229
AZN 1.835771
BAM 1.955799
BBD 2.177098
BDT 118.609918
BGN 1.958772
BHD 0.4065
BIF 3068.097874
BMD 1.077349
BND 1.443699
BOB 7.450995
BRL 5.312845
BSD 1.078299
BTN 89.909438
BWP 14.68999
BYN 3.552498
BYR 21116.045369
BZD 2.173498
CAD 1.464603
CDF 2887.296389
CHF 0.948133
CLF 0.034013
CLP 939.719349
CNY 7.688615
COP 4300.09702
CRC 569.099606
CUC 1.077349
CUP 28.549755
CVE 110.264924
CZK 24.39507
DJF 191.989867
DKK 7.462372
DOP 61.429957
DZD 145.120065
EGP 33.275977
ERN 16.160239
ETB 60.137658
FJD 2.410789
FKP 0.859337
GBP 0.858582
GEL 2.871179
GGP 0.859337
GHS 12.971991
GIP 0.859337
GMD 72.559892
GNF 9267.993578
GTQ 8.439994
GYD 225.769844
HKD 8.414425
HNL 26.593982
HRK 7.58623
HTG 142.619901
HUF 381.716032
IDR 16777.559925
ILS 3.992689
IMP 0.859337
INR 89.883626
IQD 1411.499022
IRR 45544.940072
ISK 150.463013
JEP 0.859337
JMD 167.819884
JOD 0.764384
JPY 156.069165
KES 166.819884
KGS 96.22925
KHR 4436.996926
KMF 493.264769
KPW 969.574174
KRW 1419.580431
KWD 0.332212
KYD 0.898599
KZT 494.729657
LAK 22345.984516
LBP 16206.488771
LKR 352.930755
LRD 202.811408
LSL 20.4485
LTL 3.181133
LVL 0.651678
LYD 5.211996
MAD 10.923092
MDL 19.176987
MGA 4942.996575
MKD 61.519957
MMK 2264.398431
MNT 3699.799795
MOP 8.677294
MRU 42.667066
MUR 47.522284
MVR 16.537719
MWK 1815.098742
MXN 18.689897
MYR 5.025876
MZN 68.142287
NAD 20.448495
NGN 865.65414
NIO 39.459973
NOK 11.780227
NPR 143.8549
NZD 1.75779
OMR 0.4151
PAB 1.078299
PEN 4.051797
PGK 4.019997
PHP 59.850526
PKR 305.960288
PLN 4.338897
PYG 7926.994507
QAR 3.92267
RON 4.972833
RSD 117.171919
RUB 99.283162
RWF 1356.79906
SAR 4.04058
SBD 9.131554
SCR 13.71439
SDG 647.487267
SEK 11.276511
SGD 1.444766
SHP 1.310865
SLE 24.67211
SLL 21277.648121
SOS 615.166788
SRD 40.442655
STD 22298.954388
SYP 14007.508954
SZL 20.384986
THB 38.416161
TJS 11.780192
TMT 3.770722
TND 3.372646
TOP 2.541737
TRY 31.164917
TTD 7.323995
TWD 33.855166
TZS 2701.098128
UAH 39.607273
UGX 4064.997183
USD 1.077349
UYU 42.139971
UZS 13275.990801
VEF 3830760.985659
VES 38.307658
VND 26104.172412
VUV 129.081044
WST 2.958057
XAF 655.956545
XAG 0.046825
XAU 0.000537
XCD 2.911591
XDR 0.811499
XOF 655.956545
XPF 119.331742
YER 269.687492
ZAR 20.4286
ZMK 9697.439969
ZMW 26.012982
ZWL 346.90602
  • SCS

    -0.0900

    12.53

    -0.72%

  • NGG

    -0.3400

    67.47

    -0.5%

  • RIO

    -0.2700

    70.17

    -0.38%

  • BCC

    0.4600

    111.92

    +0.41%

  • RYCEF

    0.0190

    3.649

    +0.52%

  • RELX

    0.0000

    38.96

    0%

  • VOD

    -0.1100

    8.73

    -1.26%

  • RBGPF

    -0.3460

    67.2

    -0.51%

  • GSK

    -0.0600

    35.94

    -0.17%

  • SCU

    -0.0300

    12.72

    -0.24%

  • CMSC

    -0.1000

    24.48

    -0.41%

  • SLAC

    0.0000

    10.3

    0%

  • BCE

    -0.1500

    40.61

    -0.37%

  • JRI

    -0.1200

    11.27

    -1.06%

  • BTI

    -0.2500

    29.13

    -0.86%

  • AZN

    -0.2600

    63.25

    -0.41%

  • BP

    0.6100

    35.3

    +1.73%

  • CMSD

    -0.0400

    24.27

    -0.16%

Inside information: Bioretec's Board of Directors to initiate a new CEO recruitment process
Inside information: Bioretec's Board of Directors to initiate a new CEO recruitment process

Inside information: Bioretec's Board of Directors to initiate a new CEO recruitment process

TAMPERE, Finland, Nov. 16, 2023 /PRNewswire/ -- Bioretec Ltd, a pioneer of biodegradable orthopedic implants, is initiating a new CEO recruitment process as the company's current CEO, Mr. Timo Lehtonen, shall transfer into a new role within the company. The Board of Directors and Mr. Lehtonen have reached a mutual consensus in good understanding, based on a shared vision for the company's future, to begin a recruitment process for a new CEO who will steer Bioretec to its forthcoming growth stages. Mr. Lehtonen will maintain his role as CEO with the Board's full support until the successor is appointed, ensuring stability and continuity in the leadership of the Company.

Text size:

During Mr. Lehtonen's tenure, Bioretec has reached numerous milestones, notably reforming the surgical treatment of bone fractures with biodegradable metal implants through a first-ever FDA market authorization of magnesium-based implants in the U.S., thus significantly improving patient recovery and quality of life. Furthermore, under his leadership, the Company has enhanced its international market reach with sustained double-digit (in percentages) revenue growth and solidified its status as an innovator in biodegradable technologies.

"It has been an honor to lead Bioretec since 2019, overseeing the company's dynamic growth with unwavering commitment. I deem that this is an appropriate juncture for a new leader to continue to implement the Company's vision. My deepest appreciation goes out to our executive team, the Board, and our knowledgeable staff, whose collaborative efforts have been integral to our successes in redefining bone fracture treatment and improving patients' quality of life," says Timo Lehtonen, the CEO of Bioretec.

Mr. Tomi Numminen, Chairman of the Board states, "The Board expresses its gratitude to Mr. Timo Lehtonen for his strong leadership and dedication. As we proceed with the selection of a new CEO, our focus remains on securing a leader with profound expertise in driving international business growth in alignment with Bioretec's strategic ambitions."

Further enquiries
Tomi Numminen, Chairman of the Board, tel. +358 40 581 2132 

Certified advisor
Nordic Certified Adviser AB, +46 70 551 67 29 

Bioretec in brief

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE-mark is expected to be received during the first quarter of 2024. Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

 

(Y.Berger--BBZ)